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Edited by Mike ShipstonThe glucocorticoid receptor (GR) is a ligand-dependent
transcription factor that plays a central role in inflammation.
The GR activity is also modulated via protein–protein in-
teractions, including binding of 14-3-3 proteins induced by GR
phosphorylation. However, the specific phosphorylation sites
on the GR that trigger these interactions and their functional
consequences are less clear. Hence, we sought to examine this
system in more detail. We used phosphorylated GR peptides,
biophysical studies, and X-ray crystallography to identify key
residues within the ligand-binding domain of the GR, T524 and
S617, whose phosphorylation results in binding of the repre-
sentative 14-3-3 protein 14-3-3ζ. A kinase screen identified
misshapen-like kinase 1 (MINK1) as responsible for phos-
phorylating T524 and Rho-associated protein kinase 1 for
phosphorylating S617; cell-based approaches confirmed the
importance of both GR phosphosites and MINK1 but not Rho-
associated protein kinase 1 alone in inducing GR–14-3-3
binding. Together our results provide molecular-level insight
into 14-3-3-mediated regulation of the GR and highlight both
MINK1 and the GR–14-3-3 axis as potential targets for future
therapeutic intervention.
The glucocorticoid receptor (GR) is a ligand-dependent
transcription factor that belongs to the superfamily of nu-
clear hormone receptors, a highly conserved ligandable protein
family. Ubiquitously expressed throughout the human body,
the GR regulates the expression of thousands of genes that
control a wide range of fundamental processes (1). The role of
the GR is to mediate the actions of glucocorticoids, steroid
hormones produced by the adrenal cortex and under tight
regulation by the hypothalamic–pituitary–adrenal axis (2). GR
agonists are widely prescribed drugs used in the treatment of
inflammatory and immunological conditions as well as the
treatment of some cancers. By their nature in affecting the
transcription of many genes, GR agonists are associated with
multiple effects, both beneficial and undesired, thus* For correspondence: Matthew W. D. Perry, Matthew.Perry@astrazeneca.
com.
© 2021 THE AUTHORS. Published by Elsevier Inc on behalf of American Society for
BY license (http://creativecommons.org/licenses/by/4.0/).understanding the underlying signaling network of the GR is of
great importance (2–4).
The GR is divided into three major domains: the N-terminal
domain (NTD), the DNA-binding domain (DBD), and the C-
terminal ligand-binding domain (LBD) with a short hinge re-
gion between the DBD and LBD. Upon translocation to the
nucleus, the GR binds to GR binding DNA sequences and, as a
scaffolding protein, brings different cofactors and other tran-
scription factors together to build a transcriptional complex
that regulates gene expression (1, 5, 6). In addition, the GR can
take part in nongenomic signaling (5, 6), adding another layer
of complexity, while the GR turnover is regulated by the
ubiquitin–proteasome pathway (7).
14-3-3 proteins form a family of eukaryotic regulatory
proteins that act as dimers, principally heterodimers, which
recognize and bind to specific pairs of phosphorylated serine/
threonine residues, thus forming part of a regulatory system
with kinases and phosphatases (8, 9). 14-3-3 proteins are
involved in regulating a large number of cellular processes,
such as cell cycle progression, apoptosis, intracellular protein
trafficking, and signal transduction (8). More than 200 struc-
turally and functionally diverse 14-3-3 protein partners have
been identified (10). 14-3-3 has been, for example, reported to
interact with numerous nuclear hormone receptors to modu-
late their activity, including the estrogen receptor α (ERα) (11),
estrogen-related receptor γ (ERRγ) (12), and pregnane X re-
ceptor (13).
Early evidence for the interaction between the 14-3-3 and
GR came from yeast two-hybrid studies (14) and immu-
noaffinity chromatographic studies on rat liver cytosol (15).
The 14-3-3 isoform η has been reported to bind the GR LBD
and increase the GR transcriptional activity through blocking
the ubiquitin–proteasome GR degradation pathway (14, 16).
The 14-3-3 β and γ isoforms have been found to bind the full-
length GR and to upregulate the GR activity in a ligand-
dependent manner (17). The GR transcriptional activity was,
however, repressed by phosphorylation of S134 in a p38
MAPK (p38 mitogen-activated protein kinases)-dependent
manner, driving GR interaction with 14-3-3ζ (18).J. Biol. Chem. (2021) 296 100551 1
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GR phosphorylation by MINK1 induces interaction with 14-3-3Interestingly, 14-3-3σ has been reported to bind two different
portions of the GR: GR S134 or the GR LBD and to antagonize
the GR transcriptional activity (17, 19, 20). The interaction
between the 14-3-3 and GR has been suspected to play a role
in pathological inflammatory disorders (18) and cancer (20).
Given this background, we wanted to explore the role of the
GR–14-3-3 protein–protein interaction using a bottom-up
molecular approach because information on this level is
virtually absent. Identification of the GR residues, whose
phosphorylation is recognized by 14-3-3, and the kinases
responsible for phosphorylation of these GR sites is crucial to
gain this molecular-level insight into the mechanism under-
lying the 14-3-3-mediated GR regulation. Herein, we explore
for the first time this molecular mechanism and report on the
phosphosites of the GR that are recognized by 14-3-3. The
GR–14-3-3 interaction was first investigated at the GR peptide
level and then extended to the GR LBD and finally to full-
length proteins in cells to validate the relevance of the pep-
tide studies. We found that T524 of the GR is the most
important phosphosite, particularly in association with S617.
We also found that the kinase misshapen-like kinase 1
(MINK1), not previously associated with the GR, phosphory-
lates the key T524 residue and that, in a cellular system, this
kinase is required for most of the binding of the GR to 14-3-3.
This work thus contributes to unraveling the long-standing
question on the 14-3-3 regulation of GR signaling pathways,
assessing the GR–14-3-3 protein–protein interaction impli-
cation in the disease state and highlighting both MINK1 and
the GR–14-3-3 axis as potential targets for future therapeutic
intervention.
Results
Binding of 14-3-3 to phosphopeptides, centered on putative
14-3-3-binding sites of the GR
Although 14-3-3 proteins can recognize some unphos-
phorylated sequences in nonphysiological contexts, such as
R18 and exoenzyme S (21, 22), the normal recognition ele-
ments in binding with 14-3-3 are phosphoserines and phos-
phothreonines (9). Potential phosphosites on the GR for
recognition by 14-3-3 proteins were identified from literature
reports and by the use of the 14-3-3-Pred webserver (www.
compbio.dundee.ac.uk/1433pred) (23) (Fig. 1A). We synthe-
sized 13-mer peptides centered on each of these residues and
measured their affinity to 14-3-3ζ and σ by both fluorescence
polarization (FP) and surface plasmon resonance (SPR).
Multiple potential phosphosites on the GR have been re-
ported in the literature including T8, S45, S113, S134, S203,
S211, S226, S234, S267, and S404 (6, 24). All are part of the
NTD and, apart from T8 and S404, they are located within the
transactivation domain activation function 1, suggesting a role
in the modulation of the GR transcriptional activity (6, 24).
Surprisingly, only one of these phosphosites, GR S134, was
identified as a putative 14-3-3-binding site by the prediction
algorithm. The 13-mer peptide centered on GR S134 was the
only phosphopeptide, from this set, to show an interaction2 J. Biol. Chem. (2021) 296 100551with 14-3-3 (Kd = 90 and 110 μM with 14-3-3ζ and 14-3-3σ,
respectively) (Fig. 1B).
Seven putative GR phosphorylation sites were identified by
the algorithm as candidates for recognition by 14-3-3 proteins:
S83, S134, T493, T524, T561, S617, and T635. Six of these 13-
mer GR peptides showed binding with 14-3-3ζ and σ, the
exception being pT493. Peptides centered on the GR residues
pT524 and pS617 were found to be the strongest binders with
Kds in the low micromolar range (Fig. 1, B–F, Fig. S1). Of note,
these two sites belong to the GR LBD.
Interaction of 14-3-3 with a dimeric peptide: GR_pT524-pS617
14-3-3s act as a dimer and thus effectively provide 2
amphipathic binding grooves (8). Many 14-3-3 targets (PKC,
C-Raf, CFTR, Gab2) have been shown to interact through
tandem phosphosites simultaneously, greatly increasing their
binding affinity with 14-3-3 (25–28). Hence, a dimeric peptide,
GR_pT524-pS617, consisting of the two 13-mers GR_pT524
and GR_pS617, identified above, linked by a pentaglycine
moiety to permit flexibility (25), was synthesized and tested for
binding to 14-3-3ζ. The dimeric peptide displayed a remark-
able avidity effect, with a 1000-fold improvement of its binding
affinity with 14-3-3ζ, compared with the individual monomers,
and a Kd of 18 nM, one of the highest affinities reported for a
14-3-3 motif (25–28) (Fig. 2 and Fig. S1).
Previous work has reported 14-3-3 to interact with phos-
phosites from different domains of its partner proteins (29).
Hence, the phosphosites from the GR NTD and GR LBD could
also be envisioned to interact simultaneously with a 14-3-3
dimer. We had identified two potential 14-3-3-binding sites in
the NTD, S83 and S134, from the bioinformatic analysis. To
test this hypothesis, similar 31-mer peptides containing
pentaglycine-linked 13-mers, GR_pS83-pT524, GR_pS134-
pT524, and GR_pS83-pS134, were synthesized. These pep-
tides also showed significantly increased binding affinity with
14-3-3ζ compared with the monomers, but were at least 15-
fold weaker than GR_pT524-pS617 (Fig. 2).
Identification of GR_pT524-pS617-binding hotspots by
mutation and alanine scan
We synthesized 24 peptides where each amino acid of the
31-mer GR_pT524-pS617, except the pentaglycine section,
was replaced in turn by alanine. Upon replacement of the
phosphothreonine pT524, the binding to 14-3-3 decreased by
6700-fold, from Kd = 18 nM to Kd = 120 μM. Mutation of the
phosphoserine pS617 had a less marked effect and led to a 72-
fold loss in potency resulting in a Kd of 1.3 μM. The two
phosphoresidues are, as expected, the key residues in the
binding by 14-3-3 to that doubly phosphorylated peptide. P526
proved to be the most important nonphosphorylated residue
with mutation of P526 resulting in an almost 70-fold decrease
in potency (Kd = 1.2 μM). Smaller effects were observed for
R614 and K518, resulting in a 12-fold (Kd = 220 nM) and 6-
fold (Kd = 110 nM) reduction in binding affinity, respectively
(Table 1 and Table S1).
GR phosphorylation by MINK1 induces interaction with 14-3-3To further understand the role of pT524, a diphospho-
serine analogue (GR_pS524-pS617) was synthesized. This
peptide showed an 8-fold reduction in potency (Kd =
140 nM), revealing the importance of the singular methyl
group of T524. Even so, the affinity drop for pS524 to A524
was still more than an order of magnitude larger than the
drop for the pS617 to A617 substitution, highlighting the
unexpected relative importance of pT524 versus pS617. ThisFigure 1. Interaction of the GR monophosphopeptides with 14-3-3ζ. A, s
located at the interface of each GR domain is reported below the sequence. B,
the key residues and their binding affinity (Kd) measured by FP. Binding sites o
red. The most potent GR peptides are highlighted in gray. C, Kd of the tw
concentration–response curves of FP assays of seven peptides centered on pre
GR peptides with 14-3-3ζ measured by SPR at two different peptide concentrat
two most potent peptides with 14-3-3ζ. All measurements were performed as
experiments. FP, fluorescence polarization; GR, glucocorticoid receptor; SPR, sis particularly surprising, given the similar affinities for the
two individual 13-mers but suggests that the artificial
boundary conditions of the linked peptides influence one site
more than the other. The potent binding of a diphosphory-
lated GR peptide with 14-3-3 is in line with the thermody-
namic model for multivalency in 14-3-3 protein–protein
interactions (30). The effect of the individual phosphosites
on the strength of GR_pT524-pS617 binding could thus bechematic representation of the GR sequence. The number of the residues
amino acid sequences of the monophosphorylated GR peptides centered on
f the GR from the literature are depicted in bold black and prediction in bold
o most potent monophosphorylated GR peptides measured by SPR. D,
dicted 14-3-3 binding sites with 14-3-3ζ. E, affinity of monophosphorylated
ions (33 and 100 μM). F, concentration–response curves of SPR assays of the
triplicates, and the error bars represent the SD of these three independent
urface plasmon resonance.
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Figure 2. Interaction of the GR doubly phosphorylated peptides with 14-3-3ζ. A, binding affinity (Kd) of the diphosphorylated GR peptides measured by
FP. The most potent GR peptide is highlighted in gray. B, binding affinity (Kd) of GR_pT524-pS617 measured by SPR. C, concentration–response curves of FP
assays of the four diphosphorylated GR peptides with 14-3-3ζ. D, concentration–response curve of SPR assays of GR_pT524-pS617 with 14-3-3ζ. Mea-
surements were performed as triplicates, and the error bars represent the SD of these three independent experiments. FP, fluorescence polarization; GR,
glucocorticoid receptor; SPR, surface plasmon resonance.
GR phosphorylation by MINK1 induces interaction with 14-3-3simulated, assuming an average effective molarity value of
10 mM (Equation S1).
Crystallization of GR_pT524-pS617, GR_pT524, and GR_pS617
with 14-3-3ζ
The mechanistic details of the GR–14-3-3 interaction were
further resolved by determining the crystal structures of 14-3-
3ζ in complex with GR_pT524, GR_pS617, and GR_pT524-
pS617. GR_pT524 was cocrystallized with 14-3-3ζ, and the
crystal structure was solved to a resolution of 2.09 Å [Protein
Data Bank (PDB) code 6YO8]. This high-resolution crystal
structure allowed us to assign 12 of 13 amino acids of the GR
peptide. Two GR_pT524 peptides were found to bind the two
respective central binding channels of one 14-3-3 dimer in an
extended conformation. Details of the interaction showed that
electrostatic effects dominated, with pT524 bound in the
positively charged pocket of the 14-3-3 monomer made from
K49, R56, and R127. Other polar contacts were observed be-
tween the peptide backbone and 14-3-3 residues, such as N173
and N224 (Table 2 and Fig. S2A).
The structure of GR_pS617 with 14-3-3ζ was solved to a
resolution of 2.01 Å (PDB code: 6YMO). Similar to GR_pT524,
2 GR_pS617 peptides were observed to interact with one 14-3-
3 dimer and pS617 made tight electrostatic contacts with the
positively charged pocket of 14-3-3. Interestingly, the electron
density allowed us to assign only 6 of 13 amino acids (Table 2
and Fig. S2B).4 J. Biol. Chem. (2021) 296 100551GR_pT524-pS617 was cocrystalized with 14-3-3ζ, and the
complex was solved to a resolution of 2.75 Å (PDB code
6YOS). One diphosphorylated GR peptide was bound to one
14-3-3ζ dimer. The electron density allowed the assignment of
18 of 31 amino acid residues. The pentaglycine moiety was not
visible in the electron density because of its flexibility. How-
ever, the distance between L528 and Y613, about 22 Å, is
sufficient to be bridged by 9 residues (Fig. 3, A and B), sup-
ported by computational modeling of the pentaglycine linker
(chapter 6 of the Supporting information). The crystal struc-
ture of GR_pT524-pS617 interacting with 14-3-3ζ was
consistent with the structures of GR_T524 and GR_S617
cocrystallized with 14-3-3ζ. The main interactions between the
phosphorylated residues and 14-3-3 were in line with the
GR_pT524-pS617 alanine scan results and previous published
crystal structures of phosphopeptides interacting with 14-3-3
(25, 26). Many residues pointed their side chains away from
14-3-3, consistent with the observation from the alanine scan
where mutation had a relatively small impact on the binding
affinity with 14-3-3 (Fig. 3C and Fig. S2, C–E). A proline at
position +2 relative to the phosphorylated serine/threonine
residue, such as P526, is a common feature of 14-3-3-binding
motifs 1 and 2, and this amino acid produces a sharp change in
the chain direction (9). P526 of GR_pT524-pS617 adopts a cis-
conformation. On one side, it allows the carbonyl oxygen of
L525 at the position +1 to form a hydrogen bond with the
amino groups of K120 and N173. On the other side, P526
Table 1
Binding affinity of mutated GR_pT524-pS617
FP, fluorescence polarization.
Binding affinity (Kd and pKd) of GR_pT524-pS617, relevant peptides from the alanine scan, and GR_pS524-pS617. The residues mutated into alanine are depicted in bold black and
the phosphorylated sites in bold red. Measurements were performed as triplicates.
GR phosphorylation by MINK1 induces interaction with 14-3-3induces the peptide exit from the binding groove and avoids a
clash of the remaining portion of the peptide with S45 and
K49. The role of the proline in the structure was supported by
the alanine scan. This turn creates a new pocket at the inter-
face of the GR peptide and 14-3-3. Similarly, a second pocket is
formed between GR residues 618 to 621 and the second 14-3-3
unit (Table 2 and Fig. 3). Of note, an alternative orientation of
GR_pT524-pS617 in the crystal structure with 14-3-3ζ could
not be totally excluded and is described in chapter 6 of the
Supporting information.
Assessment of the GR LBD phosphorylation profile by kinase
screening
The two potential 14-3-3-binding phosphosites identified
here, pT524 and pS617, are situated within the GR LBD.
Hence, we aimed to test the binding affinity of the doubly
phosphorylated full-length GR LBD with 14-3-3. The kinase(s)
responsible for phosphorylation of the GR LBD have not yet
been reported. We therefore aimed to identify the relevant
kinase(s). The expression of the WT human GR LBD from
Escherichia coli was unsuccessful because of solubility prob-
lems. Switching to the GR LBD mutant F602S (31) allowed us
to express sufficient GR F602S N514-K777, in the presence of
dexamethasone to be purified and used as a substrate for
candidate kinases. The phosphorylation profile of the GR LBD
was determined in a radiometric protein kinase filter-binding
assay (performed by ProQinase GmbH, Germany) in which
the activity of 245 serine/threonine kinases was measured
(Fig. S3). This phosphorylation profiling showed a differential
ability of the GR LBD to act as a substrate for the tested ki-
nases (Fig. S4). We observed that 38 kinases displayed an ac-
tivity ratio above 3 with 12 kinases above 5. MST2, MAP4K4,
MST1, and TAOK2 were the kinases with the highest ratio, 19,
16, 14, and 13, respectively (Table S2). All of them belong to
the STE20 kinase family, being upstream activators of the p38
mitogen-activated protein kinases pathways. The 12 kinases
with the highest activity ratios were selected for a follow-up
assay, and the phosphorylation profile of the GR LBD by the
12 selected kinases was determined. MAP4K4, MINK1, MST1,
MST2, and Rho-associated protein kinase 1 (ROCK1) were
observed to phosphorylate the GR LBD (Fig. S5). The varying
response may be due to the activity rate of the particular ki-
nases having different kinetics under the chosen conditionsand since the ATP concentration was fixed at 1 μM, regardless
of the ATP-Km of each kinase.
Phosphorylation of the GR LBD by MAP4K4, MINK1,
MST1, MST2, and ROCK1 followed by enzyme digestion and
analysis by MS revealed different phosphorylation patterns
(Table 3). MAP4K4 showed monophosphorylation and
diphosphorylation at T519 and T562. MST1 and MST2 both
phosphorylated T562, T668, S682, and S746; each also phos-
phorylated additional sites, although these sites were markedly
weaker in the LC-MS analysis. MST2 showed a wider phos-
phorylation pattern than MST1 with up to seven phosphory-
lations observed. The two sites we had identified as most
promising for 14-3-3 recognition (T524 and S617) were
phosphorylated by MINK1 and ROCK1, respectively. In
particular, ROCK1 phosphorylated two different sites, T519
and S617, while MINK1 gave mainly monophosphorylation
and diphosphorylation of T524 and T562, with traces of
phosphorylation at T635 (Table 3 and Fig. S6). Thus, the
screening showed that MINK1 and ROCK1 can phosphorylate
GR T524 and S617, respectively, in vitro.
MINK1 phosphorylates the GR LBD driving the interaction with
14-3-3
The ability of the GR LBD, phosphorylated by either MINK1
or ROCK1, to interact with 14-3-3 was investigated. A far-
Western blotting overlay assay was performed where we
assessed the capacity of the different phosphorylated GR LBDs,
immobilized on a membrane, to bind the two recombinant
yeast isoforms of 14-3-3 tagged with digoxigenin (BMH1-
BMH2-digoxigenin). In this assay, the GR LBD phosphory-
lated by MINK1 showed direct interaction with 14-3-3 in a
dose-dependent manner, whereas the GR LBD phosphorylated
by ROCK1 and the unphosphorylated GR LBD did not
(Fig. 4B), highlighting the specificity and sensitivity of the as-
says toward phosphorylated substrates.
MINK1 phosphorylates the GR LBD at residues T524 and
T562 and to a lesser extent T635. T524 and T635 have been
identified by the algorithm as plausible 14-3-3-binding sites
with T561 but not T562. The 13-mer peptide centered on
pT562 showed a weak interaction with 14-3-3ζ (Kd = 200 μM).
Interestingly, the 51-mer peptide GR_pT524-pT562, consist-
ing of the two 13-mer peptides GR_pT524 and GR_pT562
with the native sequence as a linker, did not show a similarJ. Biol. Chem. (2021) 296 100551 5
Table 2
Data collection and refinement statistics (molecular replacement)
Parameters
Binary complex of 14-3-3ζ with
human glucocorticoid receptor
pT524 peptide
Binary complex of 14-3-3ζ with
human glucocorticoid receptor
pS617 peptide
Binary complex of 14-3-3ζ with
human glucocorticoid receptor
pT524 pS617 peptide
PDB entry 6YO8 6YMO 6YOS
Data collection
Space group C2 P212121 P43212
Cell dimensions
a, b, c (Å) 158.65, 99.88, 84.81 72.28, 104.35, 112.43 60.21, 60.21, 284.21
α, β, γ () 90.00, 93.73, 90.00 90.00, 90.00, 90.00 90.00, 90.00, 90.00
Resolution (Å) 84.47–2.09 (2.12–2.09) 47.33–2.02 (2.02–2.07) 58.90–2.75 (2.90–2.75)
Rmerge 0.06 0.08 0.11
I/σI 9.0 (0.6) 12.07 (0.53) 12.4 (1.3)
Completeness (%) 98.3 (97.8) 99.6 (95.8) 98.3 (94.0)
Redundancy 3.4 (3.4) 6.5 (6.3) 9.4 (6.9)
Refinement
Resolution (Å) 60.85–2.09 47.33–2.02 58.90–2.75
No. of reflections 76,616 56,503 14,250
Rwork/Rfree 0.224/0.235 0.212/0.228 0.265/0.292
Clashscore 8 2 8
Ramachandran outliers (%) 0.2 0 0
Sidechain outliers (%) 4.0 2.0 5.8
RSRZ outliers (%) 6.0 7.9 7.4
Matthews coefficient (Å3/Da) 2.16 2.05 2.49
Solvent content (%) 43.08 39.99 50.60
No. of atoms
Protein 7693 3769 3690
Ligand/ion 0 25 0
Water 240 236 0
B-factors (Å2)
Protein 76.7 78.2 92.8
Ligand/ion - 59.5 -
Water 68.0 68.9 -
RMSD
Bond lengths (Å) 0.72 0.49 0.90
Bond angles () 0.69 0.60 0.86
Interface parameters
Buried surface area (sq Å) 761.8 (46.1%) 525.8 (63.1%) 1247.4 (43.3%)
Interface area (sq Å) 675.7 460.0 1132.5
Delta G (kcal/mol) −12.2 −3.9 −16.9
Binding energy (kcal/mol) −18.0 −16.9 −27.7
p value 0.5042 0.5829 0.5381
Hydrogen bonds 13 11 24
Effect of crystal contacts The closest crystallographic neighbor
is over 4 Å away and is therefore
unlikely to affect the binding of
GR_pT524
The closest crystallographic neighbor
is over 4 Å away and is therefore
unlikely to affect the binding of
GR_pS617
The closest crystallographic neighbor
is over 4 Å away and is therefore
unlikely to affect the binding of
GR_pT524-pS617
PDB, Protein Data Bank.
Values in parentheses are for highest resolution shell.
GR phosphorylation by MINK1 induces interaction with 14-3-3avidity effect as previously observed for GR_pT524-pS617. No
significant trend has been reported between the effective
molarity and the linker length (30, 32). Instead, the effective
molarity depends on the flexibility of the linker between the
two different binding sites. Thus, the binding affinity of
GR_pT524-pT562 with 14-3-3ζ (Kd = 23 and 15 μM, measured
by FP and SPR, respectively) and its low effective molarity
(0.2 mM) might suggest a more structured linker. Crystal
structure analysis (PDB code: 1M2Z) placed GR T562 in the
helix 3, which forms the spine of the protein. It would be
unlikely that this helix changes its structure, questioning the
ability of GR T562 to interact with 14-3-3 proteins.Interaction between full-length GR and 14-3-3
The interaction between the full-length GR and 14-3-3 was
investigated in a cellular system to validate the relevance of the
peptide studies. In an initial experiment, HEK293 and U2OS
cells were transiently transfected with the WT GR and, after
overnight starvation, the cells were treated with a panel of6 J. Biol. Chem. (2021) 296 100551stimuli that have previously been shown to promote phos-
phorylation of 14-3-3-binding sites of other target proteins
(33). Results from co-immunoprecipitation (Co-IP) experi-
ments and far-Western blotting overlay assay showed that the
GR interacted with 14-3-3 proteins upon stimulation with
forskolin (a cell-permeable diterpenoid which activates ade-
nylyl cyclase, increases intracellular cAMP concentration and
thus activates PKA) and calyculin A (a cell-permeable potent
and selective protein phosphatase inhibitor) (Fig. S7).
The role of the previously identified GR phosphosites in the
binding with 14-3-3 was investigated in cells. U2OS cells were
transiently transfected with the WT GR or the GR double
mutant, T524A S617A, before treatment with calyculin A.
Under our experimental conditions, Co-IP and far-Western
blotting overlay experiments revealed a significant decrease,
about 35%, of the interaction between the 14-3-3 and GR
double mutant as compared with the WT GR (Fig. 4, C and D).
These results confirm the interaction between the GR and 14-
3-3 and highlight the importance of the phosphorylation of the
2 GR residues T524 and S614.
Figure 3. Crystal structure of GR_pT524-pS617 bound to 14-3-3ζ dimer. A, the location within the GR sequence of the two 13-mer peptides centered on
pT524 and pS617, respectively, and sequence of GR_pT524-pS617. The framed amino acids were assigned in the X-ray structure. B, surface representation of
14-3-3ζ dimer (white and gray solid surface) complexed with GR_pT524-pS617. Residues 520 to 528 are depicted in magenta and residues 614 to 623 in
green. The black dashed line shows amino acid residues, not observed in the electron density, connecting the two binding sites. C, details of the interaction
between GR_pT524-pS617 and 14-3-3ζ. Polar interactions are depicted as black dotted lines and hydrophobic contracts as magenta or white spheres with a
semitransparent surface. GR, glucocorticoid receptor.
GR phosphorylation by MINK1 induces interaction with 14-3-3Upon stimulation with forskolin or calyculin A, MINK1 also
interacts with 14-3-3 (Fig. S8) (consistent with unpublished
data by Gavuthami Murugesan and CM, University of Dun-
dee). Thus, the GR–14-3-3 interaction and the MINK1–14-3-3
interaction are both promoted in parallel in cells stimulated
with forskolin and calyculin A (Fig. S7). We established that
U2OS cells have a very low endogenous expression of MINK1,
as no signal from this kinase could be detected by Westernblotting (Fig. S9). Therefore, U2OS cells were either trans-
fected with the WT GR or cotransfected with the WT GR and
MINK1. In the absence of further stimulation, no GR–14-3-3
interaction was observed in either cells. Stimulation with
calyculin A increased the level of phosphorylated GR by pre-
venting GR dephosphorylation, so that the protein was capable
of binding to 14-3-3 in a far-Western blotting overlay. This
interaction increased, by about 70%, in the presence ofJ. Biol. Chem. (2021) 296 100551 7
Table 3
Phosphorylation of the GR LBD by five kinases identified from the kinase screen
GR, glucocorticoid receptor; LBD, ligand-binding domain; MINK1, misshapen-like kinase 1; ROCK1, Rho-associated protein kinase 1.
For each kinase, intact mass and peptide mapping enable the identification of the phosphorylation state and phosphorylation sites. The kinases further investigated are highlighted
in gray.
GR phosphorylation by MINK1 induces interaction with 14-3-3overexpressed MINK1 (Fig. 4, E and F). Together these results
suggest that activated MINK1 kinase phosphorylates the GR
and triggers the GR–14-3-3 protein–protein interaction.
Discussion
In this study, we systematically investigated the GR–14-3-3
interaction at a GR peptide level, using biophysical assays,
alanine scanning, and X-ray crystallography. We particularly
focused on 14-3-3σ and 14-3-3ζ, two very representative iso-
forms, because the seven 14-3-3 isoforms hold a high sequence
similarity, notably in the amphipathic binding groove (34).
Two GR phosphorylation sites, within the GR LBD, were
identified as mediating the strongest binding to 14-3-3: T524
and S617. The GR LBD has been previously reported to
interact with 14-3-3, using yeast two-hybrid assays, GST pull-
down, and Co-IP experiments, while the GRβ isoform, which
shares the same NTD and DBD but contains a different LBD,
did not (14, 19, 20). 14-3-3-binding sites are mostly located
within intrinsically disordered regions or bordering the func-
tional domains (35). Interestingly, the GR residue T524 was
anticipated to be within an intrinsically disordered region
(globplot.embl.de), and the crystal structure analysis of the GR
LBD placed this residue within a random coil (36). S617 was
found in a relatively disordered area, that is, the loop between
helix 5 and β-sheet 1, but within an ordered domain, which, to
the best of our knowledge, might be one of the first examples
of a 14-3-3-binding site located in ordered regions. Mecha-
nistically, after phosphorylation, 14-3-3 partners bind in the
amphipathic groove of 14-3-3, leading to a disorder-to-order
transition, entropically disadvantageous but enthalpically
favorable, driven by the formation of charge–charge in-
teractions with the phosphate group and hydrogen bonding to
neighboring residues (35).
One site, GR S134, previously reported to be a 14-3-3
recognition site and predicted by the algorithm used in this
study, matches the mode-1 binding motif, RSX-pS/T-XP,
where X is any amino acid (cysteine excluded) and pS/T is a
phosphorylated serine or threonine. Phosphorylation of GR
S134, upon oxidative stimuli, was found to enhance GR
interaction with 14-3-3 proteins (18). Here, we report that
GR_pS134 interacts with the ζ and σ isoforms of 14-3-3 but
with a weaker binding affinity than the two identified sites
from the GR LBD.
The dimeric GR_pT524-pS617 peptide revealed an
impressive avidity gain over the monomeric components with
a low nanomolar affinity toward 14-3-3. Examination of the8 J. Biol. Chem. (2021) 296 100551crystal structure of the GR LBD showed that T524 and S617
are both solvent exposed, and that the distance between these
two residues in the crystal structure is 37 Å, closely corre-
sponding to the distance between the two phospho-binding
sites of 14-3-3. Other steroid hormone receptors, however,
such as the androgen and the mineralocorticoid receptors,
undergo a N–C interaction for complete transcriptional ac-
tivity (37, 38). The full-length GR has not been crystallized yet,
and an interdomain interaction through 14-3-3 binding,
namely an interaction between the NTD, such as S134, and the
LBD of the GR, could be envisioned. Our biophysical assays
showed that the affinity of GR_pS134-pT524, although 15-fold
weaker than GR_pT524-pS617, is still in the submicromolar
range (Kd = 0.55 μM), which cannot exclude a potential
interaction of GR pS134 with 14-3-3. In addition, cell-based
approaches revealed that the affinity between the GR double
mutant, T524A S617A, and 14-3-3 decreased by 35% as
compared with the WT GR, but was not abolished. These
results suggest that 14-3-3 interacts with the GR through
multiple sites. Further experiments would be necessary to fully
quantify the individual effect of the GR phosphosites in 14-3-3
binding with the full-length GR and their biological role by
monitoring GR translocation, GR transcriptional activity, or
GR protein level.
14-3-3 has been shown to interact with various nuclear
hormone receptors and modulate their activity, adding another
layer of regulation beyond ligand-driven activation. Interaction
of 14-3-3 with ERRγ, upon S179 phosphorylation, favors ERRγ
cytoplasmic localization and alters its transcriptional activity
and its ability to promote hepatic gluconeogenesis (12). Inter-
action of 14-3-3 with ERα, upon T594 phosphorylation, inhibits
ERα dimerization and transactivation (11). Interaction of 14-3-3
with the pregnane X receptor leads to the overexpression of P-
glycoprotein (also known as multidrug resistance protein 1)
(13). Previous studies on GR–14-3-3 protein–protein interac-
tion have reported on the 14-3-3 modulation of the GR activity,
with different consequences assigned, including the GR trans-
location and GR transcriptional activity (14, 16–20). These
studies focused on distinct 14-3-3 isoforms and different
cellular contexts, which could explain the seemingly conflicting
results. The 14-3-3 isoforms indeed interact with different
protein partners and have different affinities, distinct in vivo
effects on targets, and a specific tissue distribution (39–41). The
GR has been reported to dimerize through amino acids found in
the GR DBD and GR LBD such as residues P625 and I628 (42,
43). These two residues are closely located to the 14-3-3-
GR phosphorylation by MINK1 induces interaction with 14-3-3binding site of the GR, S617, and it is enticing to speculate that
phosphorylation of S617 and interaction with 14-3-3 would
negatively impact GR dimerization. To the best of our knowl-
edge, however, no study on the role of 14-3-3 in GR dimer-
ization has been reported. Co-crystallization of GR_pT524-
pS617 with 14-3-3ζ led to the identification of two new bind-
ing pockets created at the interface of the GR peptide and 14-3-
3 protein. It is enticing to speculate that these pockets (pocket
size estimation of 390 Å3) could be exploited to find a molecule
that would form positive interactions with each partner, acting
as a “molecular glue” to stabilize the GR–14-3-3 protein–
protein interaction. Such a tool compound could play a signif-
icant role in the quest to understand the physiological role of
the GR–14-3-3 protein–protein interaction.
It is of great interest to fully unravel the underlying signaling
network of the GR because of the enormous importance of GR
drugs and their widespread use, despite their many side effects.
Collectively, our results contribute to answering the long-
standing question on the 14-3-3 regulation of GR signaling
pathways and highlight both MINK1 and the GR–14-3-3 axis
as potential targets for future therapeutic intervention.
Experimental procedures
Material, instruments, reagents, antibodies, and plasmids
Detailed information is provided in Supporting information.
Peptide synthesis
General protocol for solid-phase peptide synthesis
The peptides were synthesized via Fmoc/tBu solid-phase
peptide. The first amino acid was attached to the 2-
Chlorotrityl chloride resin following method A to reach a
loading of 0.66 mmol/g. The peptide chains were then
assembled according to method B. The peptides were then
labeled by either addition of an FITC tag (method C) or N-
terminal acetylation (method D) before being cleaved from the
resin, deprotected according to method E and purified.
Method A: Attachment of the first amino acid on the 2-
chlorotrityl chloride resin
2-Chlorotrityl chloride resin (0.3–0.8 meq/g, final loading
0.66 mmol/g) was swollen in dichloromethane (DCM) for
10 min, and then the solvent was drained. The first amino acid
(1 eq) was dissolved in DCM (1 ml), and N,N-
diisopropylethylamine (DIPEA) (3 eq) was added. The solution
was added to the resin and stirred at room temperature (RT)
under nitrogen bubbling. After 10 min, DIPEA (7 eq) was added
to the resin and the reaction mixture was stirred for 40 min.
MeOH (0.8 μl/mg of resin) was added to the resin and was
stirred for 10 min. The mixture was drained, and the resin was
washed with dimethylformamide (DMF) (3×) and DCM (3×).
Method B1: Automated Fmoc solid-phase peptide synthesis,
Biotage Initiator + Alstra automated microwave peptide synthesizer
The resin was swollen with DMF (2×), and the Fmoc Nα-
protecting group was removed with 20% piperidine in DMF(2×; 3 min then 10 min) at RT. The amino acids dissolved in
DMF (0.3 M) were repeatedly coupled with 1-[bis(dimethyla-
mino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid
hexafluorophosphate (HATU) (3 eq) in N-methyl-2-
pyrrolidone (NMP) (0.5 M) and DIPEA (6 eq) in NMP (2 M)
at RT for 45 or 60 min. The resin was finally washed with
DCM (6×).
Method B2: Automated Fmoc solid-phase peptide synthesis,
Biotage Syro II automated parallel peptide synthesizer
The resin was swollen with DMF (6×), and the Fmoc Nα-
protecting group was removed with 40% piperidine in DMF
(3 min) followed by 20% piperidine in DMF (10 min) at RT.
The amino acids (4 eq) dissolved in DMF (0.5 M) were
repeatedly coupled with HATU (4 eq) in DMF (0.48 M) and
DIPEA (8 eq) in NMP (2 M) at RT for 40 min. The resin was
finally washed with DCM (3×), MeOH (3×), and Et2O (3×).
Method C: Addition of an FITC tag at the N-terminal position
After the final Fmoc deprotection, the resin was swollen
with DCM (2×). In the dark, FITC (3 eq) was dissolved in
DMF, and HATU (3 eq) and DIPEA (4.5 eq) were added. The
reaction mixture was added to the resin and stirred at RT
under nitrogen bubbling for 45 min. The mixture was drained,
and the resin was washed with DMF (3×) and DCM (3×).
Method D: Acetylation of the N-terminal position
After the final Fmoc deprotection, the resin was swollen
with DCM (2×). A solution of acetic anhydride (10 eq) and
DIPEA (10 eq) in DMF was added to the resin and stirred at
RT under nitrogen bubbling for 15 min before the mixture was
drained. This procedure was repeated twice, and the resin was
washed with DMF (3×) and DCM (3×).
Method E: Cleavage from resin/side-chain deprotection
A solution of TFA/water/1,2-ethanedithiol/triisopropylsi-
lane 94:2.5:2.5:1 (5 ml) was added to the dry resin. The reac-
tion mixture was shaken at RT for 3 h. TFA solution was then
collected in cold diethyl ether. The resin was rinsed with TFA
(1 ml, 3×) and the TFA solution collected. The precipitated
peptide was centrifuged, and the crude peptide was lyophilized
from acetonitrile–water.
Full-length expression and purification of 14-3-3
The σ and ζ isoforms of human 14-3-3 were cloned in the
pProEx Htb vector as 6His-Linker (MSYYHHHHHHDY-
DIPTTENLYFQGAMGS)-h14-3-3 and expressed in E. coli
BL21 (DE3)STAR competent cells. Cultures were grown in
Terrific Broth media supplemented by 3-mM MgCl2, 0.02%
glucose, 0.8% glycerol, and 50 μg/ml carbenicillin at 37 C to
an optical density at 600 nm of 0.4 to 0.6 and then induced
overnight with 0.4 mM of IPTG at 18 C to reach an optical
density at 600 nm higher than 20. Cells were harvested by
centrifugation (5000g, 20 min) and lysed using a cell disruptor
(Constant Systems Limited) at 25 kilopounds per square inchJ. Biol. Chem. (2021) 296 100551 9
Figure 4. Interaction of the GR LBD and full-length GR with pan 14-3-3. A, the location within the GR sequence of pT524 and pS617. B, far-Western
blotting overlay of the GR LBD phosphorylated by MINK1 or ROCK1 with BMH1-BMH2-digoxigenin. Unphosphorylated and in vitro phosphorylated GR
LBDs were detected using anti-6X His tag antibody. GR LBD-bound 14-3-3 proteins were detected using anti-DIG antibody. C, U2OS cells were transfected
with GFP-GR or GFP-GR T524A S617A plasmids and stimulated with calyculin A. Cell lysates were immunoprecipitated with GFP-Trap beads. The GFP-GR and
GFP-GR mutant were detected using the anti-GFP antibody, and GR-associated 14-3-3 was detected using anti-pan 14-3-3 antibody. Far-Western blotting
overlay was performed by incubation of the GR-containing membrane with BMH1-BMH2-DIG and subsequent detection of GR-bound 14-3-3 protein using
the anti-DIG antibody. D, quantification of three independent experiments. E, U2OS cells were transfected with GFP-GR or cotransfected with GFP-GR and
FLAG-MINK1 plasmids and treated as mentioned previously. FLAG-MINK1 was detected using the anti-MINK1 antibody. Far-Western blotting overlay was
performed as mentioned previously. F, quantification of three independent experiments. Data are normalized to the amount of GFP-GR and GFP-GR mutant
from the IP (immunoprecipitation) fraction. The error bars represent the SD of the three independent assays. All p values were obtained using the t test.
*p < 0.05, ****p < 0.0001. CaIA, calyculin A; GR, glucocorticoid receptor; LBD, ligand-binding domain; MINK1, misshapen-like kinase 1; OL, overlay; ROCK1,
Rho-associated protein kinase 1.
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GR phosphorylation by MINK1 induces interaction with 14-3-3(KPSI) in the lysis buffer containing 50-mM Tris, 300-mM
NaCl, 12.5-mM imidazole, 1-mM tris(2-carboxyethyl)phos-
phine (TCEP), 5-mM MgCl2, and 1 tablet protease inhibitor
Roche per 100 ml of the lysis buffer. After centrifugation
(35,000g, 45 min), the lysate was incubated with Ni-NTA
derivatized Sepharose resin (Qiagen) overnight at 4 C. The
nickel-resin was washed with the buffer containing 0.1%
Triton X-100 then with lysis buffer and the proteins were
eluted with buffer containing 250-mM imidazole. 14-3-3
proteins were further purified by size-exclusion chromatog-
raphy on a HiLoad 26/60 Superdex 75 per grade (Pharmacia
Biotech) using HBS P+ buffer (10-mM Hepes pH 7.4, 150-mM
NaCl, 0.005% v/v Tween-P20). The correct fractions were
combined, concentrated, aliquoted, frozen in liquid nitrogen,
and stored at −80 C.
Expression and purification of 14-3-3 ΔC
Human 14-3-3ζΔC (C-terminally truncated, including resi-
dues 1–231, for crystallography purposes) was cloned in the
pProEx Htb vector and expressed in E. coli BL21 (DE3)
competent cells. Cultures were grown in TB media at 37 C to
an optical density at 600 nm of 0.8 to 1 and then induced
overnight with 0.4-mM of IPTG at 18 C to reach an optical
density at 600 nm higher than 20. Cells were harvested by
centrifugation (10,000g, 15 min) and lysed using a cell dis-
ruptor (Avestin EmulsiFlex C3 Homogenizer) at 20 KPSI in
the lysis buffer containing 50-mM Tris, 300-mM NaCl, 12.5-
mM imidazole, and 2-mM β-mercaptoethanol. After centri-
fugation (40,000g, 30 min), the lysate was applied to a HisTrap
HP column (GE) and washed with the lysis buffer, and the 14-
3-3 proteins were eluted with 50-mM Tris, 300-mM NaCl,
250-mM imidazole, and 2-mM β-mercaptoethanol. The right
fractions were combined, and the full-length proteins were
dialyzed and rebuffered in 25-mM Hepes, pH 7.5, 100-mM
NaCl, 10-mM MgCl2, 0.5-mM Tris(2-carboxyethyl)phos-
phine. The His Tag was removed via TEV cleavage. The
cleavage solution was applied to the HisTrap HP column to
remove the TEV protease. The protein was further purified via
size-exclusion chromatography on a Superdex 75 (GE) using
the following buffer: 20-mM Tris, pH 7.4, 150-mM NaCl, and
2-mM β-mercaptoethanol. The correct fractions were com-
bined, concentrated, aliquoted, frozen in liquid nitrogen, and
stored at −80 C.
GR LBD expression and purification
GR N514-K777 and GR F602S N514-K777 were cloned in
the pET24a base vector as the N-terminal 6His tag with an
adjacent TEV cleavage site (ENLYFQG) and expressed in
E. coli BL21 (DE3)STAR competent cells. Cultures were grown
in autoinduction TB media 5052: TB media supplemented by
3-mM MgCl2, 0.05% glucose, 0.5% glycerol, 0.2% lactose,
100 μg/ml kanamycin, and 100-μM dexamethasone at 37 C to
an optical density at 600 nm of 1 and then induced for 48 h at
16 C. The culture was centrifuged (5000g, 20 min), and the
pellet was lysed using a cell disruptor (Constant Systems
Limited) at 25 KPSI in the lysis buffer containing 50-mM Tris,pH 8, 1% CHAPS, 10% glycerol, 1-mM TCEP, 50-μM dexa-
methasone, and 1 tablet protease inhibitor Roche per 100 ml of
the lysis buffer. The lysate was incubated with Ni-NTA
derivatized Sepharose resin (Qiagen) overnight at 4 C
washed with the buffer containing 60-mM NaCl and 30-mM
imidazole and eluted with the buffer containing 30-mM
NaCl, 300-mM imidazole. GR LBD proteins were further pu-
rified by size-exclusion chromatography on a HiLoad 16/60
Superdex 75 per grade (Pharmacia Biotech) using the
following buffer: 50-mM Tris, pH 9, 1-mM TCEP, and 25-μM
dexamethasone. The correct fractions were combined,
concentrated, aliquoted, frozen in liquid nitrogen, and stored
at −80 C.
FP assay with GR phosphorylated peptides and 14-3-3
The FITC-labeled peptides were solubilized to a final con-
centration of 60 nM (for the monophosphorylated peptides) or
10 nM (for the doubly phosphorylated peptides) and were
titrated with 14-3-3ζ or 14-3-3σ in concentration dilution se-
ries from 300 μM or 150 μM, depending on the binding affinity
of the peptide, in a 384-well flat-bottom black polypropylene
microplate (Greiner Bio-One). After 30-min incubation at RT,
the plates were read on a plate reader PHERAstar (BMG
LABTECH GmbH) for FP signal using white light and stan-
dard excitation (485 nm) and emission (520 nm). Measure-
ments were performed as triplicates. Binding data were fit to a
standard Hill equation using the software Genedata Screener.
The figures were made using the software GraphPad Prism 8.
FP data were expressed as millipolarization (mP) units, and the
dynamic range (ΔmP) was the difference of the signals from
the bound peptide and free peptide. Errors are the standard
error of the fit.
SPR assays with GR phosphorylated peptides and 14-3-3
SPR binding assays were performed using a Biacore 3000
(GE Healthcare). 6His-tagged 14-3-3 proteins (3 μM) were
immobilized on a SPR sensor chip NTA derivatized car-
boxymethyl dextran hydrogel (XanTec Bioanalytics) at 4000
RU for 14-3-3σ and 2000 RU for 14-3-3ζ according to the
manufacturer’s instructions. A 96-well V-shaped poly-
propylene microtiter plate was prepared with different GR
peptides concentrations in HBS P+ buffer and normalized to
1 or 3% v/v DMSO, depending on the maximum peptide
concentration, using the HP D300 Digital Dispenser (Hew-
lett-Packard Company). In the dose–response assay, 10 di-
lutions of the GR peptide from 300 μM or 45 μM, depending
on the peptide binding affinity, were performed. The peptide
samples were injected using the HBSP + buffer with 1 or 3%
v/v DMSO at a continuous flow rate of 20 μl/min for 1 min
on the immobilized 14-3-3 and before the next injection
2.5 min after. An extra waiting time of 12.5 min was set to
allow complete dissociation of the doubly phosphorylated
peptides. Measurements were performed as triplicates.
When necessary data were corrected using a solvent
correction curve, binding data were fit to a standard Hill
using the software Genedata Screener and the figures wereJ. Biol. Chem. (2021) 296 100551 11
GR phosphorylation by MINK1 induces interaction with 14-3-3made using the software GraphPad Prism 8. Errors are
standard error of the fit.
X-ray crystallography studies
Sitting-drop cocrystallization of 14-3-3ζ and GR peptides
Crystals were grown using the sitting-drop vapor diffusion
crystallization method by mixing 14-3-3ζΔC with a mono-
phosphorylated GR peptide in a 1:2 ratio or with a doubly
phosphorylated peptide in a 1:1 ratio with a resulting protein
concentration of 10 mg/ml in a crystallization buffer con-
taining 20-mM Hepes, pH 7.5, 2-mM MgCl2, and 2-mM DTT.
Sitting drops were formed by mixing equal volumes of protein/
peptide solution and precipitant (2 × 100 nl) on a 96-well Art
Robbins Flat Ledge plate (Hampton Research) using a nano-
liter liquid handler mosquito (SPT Labtech) and equilibrated
over an 80-μl reservoir at 4 or 20 C. Crystals were harvested
after a few days, soaked in a cryoprotectant containing the
precipitant supplemented with 20% v/v glycerol, and flash-
cooled in liquid nitrogen before data collection. The precipi-
tant solutions are listed below.
GR_pT524 cocrystallized with 14-3-3ζ
The crystals were grown at 4 C using a precipitant solution
(1.29 M MgCl2, 22.5% PEG 3350, 0.1 M Tris, pH 8.3) sup-
plemented with 10% of an additive containing 40% v/v of 2,5-
hexanediol. The crystals were harvested after 8 days.
GR_pS617 cocrystallized with 14-3-3ζ
The crystals were grown at 4 C using a precipitant solution
(2.04 M ammonium sulfate, 0.2 M sodium citrate) supple-
mented with 10% of an additive containing 0.33% w/v 3-
aminobenzoic acid, 0.33% w/v 3-aminosalicylic acid, 0.33%
w/v salicylic acid, and 0.02 M Hepes sodium, pH 6.8. The
crystals were harvested after 5 days.
GR_pT524-pS617 cocrystallized with 14-3-3ζ
The crystals were grown at 20 C using a precipitant solu-
tion (0.35 M MgCl2, 24.4% PEG 3350, 0.1 M Bis Tris pH 5.5)
supplemented with 10% of an additive containing 0.06 M
CHAPS, 0.06 M Hepes, 0.06 M Tris, 0.25% w/v hexammine-
cobalt(III) chloride, and 0.02 M Hepes sodium, pH 6.8. The
crystals were harvested after 8 days.
Data collection and processing
Diffraction data were collected at the European Synchrotron
Radiation Facility in Grenoble, France (0.976 Å, 100 K, Euro-
pean Synchrotron Radiation Facility Beamline ID30B) and at
Diamond Light Source at the Harwell Science and Innovation
Campus in Oxfordshire, UK (0.916 Å, 100 K, Diamond
Beamline I04-1). Molecular replacement was performed using
Phaser from the ccp4i package and refinement, and manual
rebuilding was performed using Buster and Coot software
packages. The structures (PDB codes: 6YO8, 6YMO, and
6YOS) were refined to a resolution of 2.09 Å, 2.01 Å, and
2.75 Å with Rwork/Rfree factors of 0.224/0.235, 0.212/0.228,12 J. Biol. Chem. (2021) 296 100551and 0.268/0.291, respectively. X-ray diffraction data collection
and structure refinement statistics are summarized in Table 2.
The figures were made using the software PyMol (DeLano
Scientific LLC).
Radiometric protein kinase filter-binding assay
The kinase screen was performed by ProQinase GmbH,
Freiburg im Breisgau, Germany. A radiometric protein kinase
filter-binding assay was used for measuring the kinase activity
of the 245 serine/threonine kinases. The reaction cocktails
were pipetted into 96-well V-shaped polypropylene microtiter
plates in the following order: kinase solution (10 μl) and
buffer/ATP/test sample mixture (40 μl). The reaction cocktails
contained 60-mM Hepes-NaOH, pH 7.5, 3-mM MgCl2, 3-mM
MnCl2, 3-μM Na-orthovanadate, 1.2-mM DTT, 1-μM ATP/
[γ-33P]-ATP (8.68 × 1005 cpm per well), protein kinase
(1–400 ng/50 μl), and sample protein (5 μg/50 μl) with minor
modifications as stated in the Supporting information. Each
assay plate comprised one well for a buffer/substrate control
containing no enzyme. The assay plates were incubated at 30
C for 60 min, and the reaction cocktails were stopped with
20 μl of 10% v/v H3PO4. The reaction cocktails were trans-
ferred into 96-well glass-fiber filter plates (MultiScreen MSFC,
Millipore) and prewetted with 150 mM H3PO4, followed by
10 min incubation at RT. After washing with 250 μl of 150-
mM H3PO4 (3×) and with 20 μl of 100% ethanol and drying
for 30 min at 40 C, 50 μl of scintillator (ROTISZINT eco plus,
Roth) was added to each well and incorporation of 33Pi
(“counting of cpm”) was determined with a microplate scin-
tillation counter (MicroBeta, PerkinElmer).
Peptide mapping
The protein samples were phosphorylated as described
above with nonradioactive ATP. About 10, 5, 3, and 1 μg of
protein sample, supplemented with 25% NuPAGE LDS
sample buffer (4×) and 10% NuPAGE sample reducing agent
(10×), was run on a NuPAGE 4 to 12% Bis-Tris Protein Gels
and 1.0 mm with Mops buffer and the bands were revealed
using Coomassie Brilliant Blue. Bands of interest were cut
from the gel to be washed with water, 1:1 acetonitrile/water,
100-mM ammonium bicarbonate, and 1:1 acetonitrile/100-
mM ammonium bicarbonate successively for 10 min. The
bands were reduced and alkylated with a solution of 10-mM
DTT in 100-mM ammonium bicarbonate for 45 min at 65 C
followed by a solution of 50-mM iodoacetamide in ammo-
nium bicarbonate for 20 min in the dark. The samples were
washed with 50-mM ammonium bicarbonate, 1:1100-mM
ammonium bicarbonate/acetonitrile, and 100% acetonitrile
successively for 10 min and dried. The bands were digested
with 10 ng/μl trypsin and 12.5 ng/μl chymotrypsin in 50-mM
ammonium bicarbonate at RT overnight. The material was
extracted twice with 0.1% TFA/60% acetonitrile and then
dried before being analyzed by MS. The data files generated
were searched against the in-house or SwissProt database
using the software Mascot Daemon. The searches were then
manually verified.
GR phosphorylation by MINK1 induces interaction with 14-3-3Intact mass
The protein samples were phosphorylated as described
above with nonradioactive ATP. The samples were diluted to
0.01 mg/ml in 0.1% formic acid and 5% acetonitrile and were
analyzed by MS. The TIC peak data were used to generate the
m/z spectrum, and the data were deconvoluted to give final
mass.
Database search parameters and acceptance criteria for
identifications
Search engine and release version: Mascot Daemon, version
2.7.0
Sequence database searched: SwissProt, Human
Release version/date of sequence database searched: August
2018
The number of entries in the database actually searched:
Whole of human SwissProt database
Specificity of all proteases used to generate peptides:
Trypsin and chymotrypsin. Trypsin specificity is the C-termi-
nal side of lysine and arginine unless there is a proline on the
carboxyl side. Chymotrypsin’s main cleavage sites are after
tryptophan, tyrosine, and phenylalanine.
The number of missed and/or nonspecific cleavages
permitted: 2
Fixed modifications (including residue specificity) consid-
ered: Carbamidomethylation on cysteine (+57.021)
Variable modifications (including residue specificity)
considered: Oxidized methionine (+15.995 Da) and phos-
phorylation of threonine, serine, tyrosine (+15.966 Da)
Mass tolerance for precursor ions: ±0.6 Da
Mass tolerance for fragment ions: ±0.6 Da
Threshold score/expectation value for accepting individual
spectra: 20
Cell culture, transfection, and stimulation
The HEK293 and U2OS cell lines (American Type Culture
Collection) were cultured in Dulbecco’s modified Eagle’s me-
dium, supplemented with 10% fetal bovine serum and 1%
penicillin-streptomycin (10,000 U/ml) at 37 C in a 5% CO2
environment. For the Co-IP assay, 3 × 106 cells were seeded in
a 15-cm cell culture dish. At 60 to 70% confluence, the
HEK293 cells were transiently transfected with a mixture of 6-
μg GFP-MINK1 or GFP-GR DNA and 24-μl lipofectamine
2000 in 2-ml Opti-MEM for 24 h. At 60 to 70% confluence, the
U2OS cells were transiently transfected with a mixture of 8-μg
GFP-MINK1 or GFP-GR and/or FLAG-MINK1 DNA and 32-
μl X-tremeGENE 9 DNA in 2 ml Opti-MEM for 24 h. Stim-
ulation with forskolin, H89, IGF-1, and PI303 was preceded by
a cell starvation step where the cells were incubated with
DMEM without supplements overnight. The cells were treated
with the right compound at the concentration and during the
time stated in the table found in the Supporting information.
Co-IP assay
Cells were collected and lysed in radioimmunoprecipitation
assay buffer containing 50-mM Tris-HCl, pH 8, 150-mM NaCl,1-mM EDTA, 0.1% SDS, 1% Na deoxycholate, and 1% NP-40
supplemented with a protease inhibitor cocktail. After lysis,
the concentration of protein was quantified by the Bradford test.
The dilution/washing buffer containing 50-mM Tris HCl, pH 8,
150-mM NaCl, and 1-mM EDTA was added to reach equal
concentration, and 50 μl was saved as the input fraction for
future analysis. Equal volumes of the protein solution were
incubated with 10-μl GFP-Trap Agarose beads (ChromoTek) at
4 C for 2 h. 50 μl was saved as a flow-through fraction for
future analysis, and the beads were washed with dilution/
washing buffer (2×). 30 μl NuPAGE LDS sample buffer (4×) was
added to the beads, and proteins from the input, flow-through,
and IP fractions were denatured at 95 C for 5 min.
Eluted proteins were resolved on a NuPAGE 4 to 12% Bis-
Tris Protein Gels, 1.0 mm. The gels were transferred to pol-
yvinylidene difluoride membranes (previously activated in
methanol) that were then blocked with Intercept (TBS)
blocking buffer (LI-COR). After washing with tris-buffered
saline with Polysorbate 20 (TBST), the membranes were pro-
bed at 4 C overnight with the primary antibodies listed in
Supporting information. After washing with TBST, the
membranes were incubated with the specific rabbit IRDye
800CW secondary antibody (LI-COR) for 1 h at RT. After
washing with TBST, the blots were detected using an Odyssey
CLx Imaging system (LI-COR). Data analysis was performed
using Image Studio (LI-COR).Far-Western blot assay
Samples containing proteins from the Co-IP assay or GR
LBD in vitro phosphorylated were loaded on a NuPAGE 4 to
12% Bis-Tris Protein Gels, 1.0 mm, and separated. The gels
were transferred to polyvinylidene difluoride membranes that
were blocked with the Intercept (TBS) blocking buffer (LI-
COR). After washing with TBST, the membranes were probed
at 4 C overnight with BMH1-BMH2-digoxigenin probe
diluted in 5% bovine serum albumin TBST. After washing with
TBST, the membranes were incubated with anti-digoxigenin
antibody (R&D Systems) at 4 C overnight. After washing
with TBST, the membranes were incubated with the specific
mouse IRDye 800CW or IRDye 680LT secondary antibody
(LI-COR) for 1 h at RT. After washing with TBST, the blots
were detected using an Odyssey CLx Imaging system
(LI-COR). Data analysis was performed using Image Studio
(LI-COR). Measurements were performed as triplicates. The
figures were made using the software GraphPad Prism 8.
Experimental design and statistical rationale
Individual data points are shown when possible and always
for n ≤ 20. Clearly defined error bars are present, representing
the SD of three independent experiments.
For the investigation of the interaction between full-length
GR and 14-3-3, Western blot quantification was obtained us-
ing Image Studio (LI-COR) from three independent cell-based
assays. The significance (two-tailed p value) was assessed by t
test. Asterisks were attributed for the following significance
values: *p < 0.05 and ****p < 0.0001.J. Biol. Chem. (2021) 296 100551 13
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